High-field magnetic resonance imaging in multiple sclerosis

High-field magnetic resonance imaging in multiple sclerosis - High field MRI in MS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32247

Enrollment

120

Registered

2008-10-31

Start date

2008-12-01

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MS Multiple Sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: clinical definite MS, age 18-60 years, EDSS

Exclusion criteria

Exclusion criteria: Clinically isolated syndrome Other neurological disorders Claustrophobia Foreign non MR compatible metal objects in the body Foreign metal objects in or close to the head

Design outcomes

Primary

Measure	Time frame
Qualitative Imaging: - The increased number of visible lesions at higher field caused by the increased spatial resolution and contrast. - The changes visible in normal appearing white and gray matter by susceptibility weighteid imaging (SWI). The relation of these changes will be compared with the quantitative results. Quantitative Imaging: - The increase accuracy and reproducibility of the measured magnetic lesion characteristics of white and gray matter. The enhanced accuracy will allow a better definition of affected tissue compared to healthy tissue.	—

Measure

Time frame

Qualitative Imaging: - The increased number of visible lesions at higher field caused by the increased spatial resolution and contrast. - The changes visible in normal appearing white and gray matter by susceptibility weighteid imaging (SWI). The relation of these changes will be compared with the quantitative results. Quantitative Imaging: - The increase accuracy and reproducibility of the measured magnetic lesion characteristics of white and gray matter. The enhanced accuracy will allow a better definition of affected tissue compared to healthy tissue.

—

Secondary

Measure	Time frame
Insight in variations in brain tissue characteristics. Effects of MRI artefacts at (ultra-)high field.	—

Countries

Netherlands

Outcome results